Happy Holidays—Our $30 Gift Card just for you, and books ship free! Shop now>>

AAPS Advances in the Pharmaceutical Sciences Series

Biosimilars

Regulatory, Clinical, and Biopharmaceutical Development

Editors: Gutka, Hiten J., Yang, Harry, Kakar, Shefali (Eds.)

Free Preview
  • Discusses the regulatory landscape and policies that define and govern the approval of biosimilar therapeutics in different geographies 
  • Focus on QbD and analytical similarity for biosimilar development
  • Increase reader’s understanding of how CMC and clinical areas play a key role in biosimilar designation and approval
see more benefits

Buy this book

eBook $119.00
price for USA in USD (gross)
  • ISBN 978-3-319-99680-6
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $159.99
price for USA in USD
  • ISBN 978-3-319-99679-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

This book provides a comprehensive overview of the biosimilar regulatory framework, the development process and clinical aspects for development of biosimilars. The development path of a biosimilar is just as unique as a development path of a new drug, tailored by the mechanism of action, the quality of the molecule, published information on the reference product, the current competitive environment, the target market and regulatory guidance, and most importantly, the emerging totality of evidence for the proposed biosimilar during development. 

For the ease of readers, the book comprises of six sections as follows:

Section I: Business, Health Economics and Intellectual Property Landscape for Biosimilars

Section II: Regulatory Aspects of Development and Approval for Biosimilars

Section III: Biopharmaceutical Development and Manufacturing of Biosimilars

Section IV: Analytical Similarity Considerations for Biosimilars

Section V: Clinical aspects of Biosimilar Development

Section VI: Biosimilars- Global Development and Clinical Experience

Chapters have been written by one or more experts from academia, industry or regulatory agencies who have been involved with one or more aspects of biosimilar product development. The authors and editors have an expertise in commercialization and pricing of biosimilars, intellectual property considerations for biosimilars, chemistry manufacturing controls (CMC) and analytical development for biosimilars, regulatory and clinical aspects of biosimilar development. Besides the industry practitioners, the book includes several contributions from regulators across the globe.

About the authors

Hiten Gutka PhD., is an Associate Director Formulation Development at Oncobiologics Inc. where he works on biosimilar drug product development. He worked on formulation and stabilization of novel insulin analogues at Thermalin Diabetes LLC. He did a co-op at Medimmune LLC, in the Formulation and Drug Product Development group. Hiten got his PhD in Pharmacognosy (Pharmaceutical Biotechnology track) from University of Illinois at Chicago (UIC), College of Pharmacy. Dr. Gutka worked at Biocon, USV and Reliance Biopharmaceuticals in India, on analytical and pharmaceutical development of biosimilar Insulins and other biosimilars including cytokines and hormones. He got his Bachelors in Pharmaceutical Sciences from University of Mumbai, India and Masters in Pharmaceutical Sciences from University Institute of Chemical Technology, Mumbai, India. Hiten is a member of the American Association of Pharmaceutical Sciences (AAPS). He serves on the editorial board of the journal mAbs.

Harry Yang, Ph.D., is Senior Director and Head of Statistical Sciences at MedImmune. He has participated in industry initiatives related to Quality by Design, analytical method development and validation, and sterile drug product bioburden testing. He has 23 years of experience in drug discovery, pre-clinical and clinical study design and analysis, translational sciences, biopharmaceutical development, manufacturing, and regulatory submissions. He has authored 5 statistical books and published 14 book chapters and more than 90 papers. He received his Bachelor’s and Master’s degrees in Applied Mathematics from Peking University, and Ph.D. in Statistics from the University of Pittsburgh.

Shefali Kakar PhD., is an Executive Director, Global Head Respiratory, in the Novartis Pharmacokinetic Sciences group.  She is responsible for overseeing all aspects of pharmacokinetics sciences (ADME, PK/PD, and clinical pharmacology) for the respiratory portfolio ranging from early discovery to full development.  Dr. Kakar has over 15 years of industrial experience and has been involved in discovery and development of over 40 small molecules and protein therapeutics, including biosimilars.  Prior to joining Novartis, Dr. Kakar worked at Pfizer and also served as an Adjunct faculty at the Brown University.  She received her PhD in Pharmacology from University of Michigan.

Table of contents (25 chapters)

Table of contents (25 chapters)
  • Biosimilars 101: An Introduction to Biosimilars

    Pages 3-21

    Welch, Anna Rose

  • Innovation, Patents and Biologics: The Road to Biosimilar Competition: Factors Influencing Investment, Business Decisions and Marketing of Biosimilars

    Pages 23-48

    Blackstone, Erwin A. (et al.)

  • The Changing US Reimbursement Landscape and Biosimilars

    Pages 49-73

    Burich, Molly

  • Litigation-Related Issues Under the Biologics Price Competition and Innovation Act

    Pages 75-104

    Coggio, Brian D. (et al.)

  • Design and Implementation of Successful Regulatory Strategies in Biosimilar Development

    Pages 107-121

    Chance, Kamali

Buy this book

eBook $119.00
price for USA in USD (gross)
  • ISBN 978-3-319-99680-6
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $159.99
price for USA in USD
  • ISBN 978-3-319-99679-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Biosimilars
Book Subtitle
Regulatory, Clinical, and Biopharmaceutical Development
Editors
  • Hiten J. Gutka
  • Harry Yang
  • Shefali Kakar
Series Title
AAPS Advances in the Pharmaceutical Sciences Series
Series Volume
34
Copyright
2018
Publisher
Springer International Publishing
Copyright Holder
American Association of Pharmaceutical Scientists
eBook ISBN
978-3-319-99680-6
DOI
10.1007/978-3-319-99680-6
Hardcover ISBN
978-3-319-99679-0
Series ISSN
2210-7371
Edition Number
1
Number of Pages
XXIII, 709
Number of Illustrations
25 b/w illustrations, 93 illustrations in colour
Topics